Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. disclosed that its Secretary and Chief Legal Officer, Daniel Rabinowitz, executed an open-market sale of 330 shares of common stock on May 1, 2026 at $206.16 per share. After this transaction, he directly held 222,694 shares.
According to the footnote, the sale was made to cover tax withholding and remittance obligations related to the vesting of restricted stock units and was carried out under a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Michael Brophy submitted a Form 144 notifying proposed sales of common stock linked to Restricted Stock Units. The filing lists 482 RSUs dated 04/30/2026 and recent 10b5-1 sales on 04/29/2026 (3,070 shares for $594,789.17), 04/27/2026 (1,993 shares for $406,855.83), and 03/10/2026 (785 shares for $160,244.17). The broker listed is Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice regarding 3,000 Performance Shares associated with the issuer, dated 01/14/2026. The filing lists multiple recent open-market sales by Solomon Moshkevich in 2026, with individual transactions and proceeds recorded between 02/02/2026 and 04/29/2026.
Natera Inc reports a Schedule 13G showing Vanguard Capital Management beneficially owns 7,205,939 shares of Common Stock, representing 5.08% of the class.
The filing states Vanguard Capital Management has sole dispositive power over 7,205,939 shares and sole voting power for 1,197,443 shares. Ownership is reported on behalf of Vanguard funds and managed accounts.
Natera, Inc.'s Chief Financial Officer, Michael Burkes Brophy, reported selling a total of 5,063 shares of Common Stock in open-market transactions on April 27 and April 29, 2026, at prices around the low-$200 to high-$190 range per share.
According to the footnotes, these sales were carried out to cover tax withholding and remittance obligations tied to the vesting of Restricted Stock Units granted in 2023 and 2024, and were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly holds 58,291 shares, indicating he retains a substantial equity stake.
Natera, Inc. CEO and President Steven Leonard Chapman reported selling a total of 5,838 shares of Natera common stock in open-market transactions on April 27, 2026. The footnotes state these sales were made to cover tax withholding and remittance obligations tied to the vesting of Restricted Stock Units and were executed under written instructions intended to satisfy Rule 10b5-1(c) affirmative defense conditions.
Natera, Inc. President and Chief Business Officer John Fesko sold a total of 1,688 shares of common stock on April 27, 2026 in two open-market transactions at prices of about $204 per share. According to the disclosure, these sales were executed to satisfy tax withholding and remittance obligations arising from the vesting of Restricted Stock Units and were carried out under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Natera, Inc. president Solomon Moshkevich reported routine share sales tied to tax withholding obligations. On April 27, 2026, he sold a total of 2,182 shares of Natera common stock in open-market transactions at prices around $204 per share.
The footnotes explain that both sales were executed solely to cover tax withholding and remittance arising from the vesting of Restricted Stock Units granted in January 2023 and January 2024. The transactions were carried out under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, sold a total of 1,861 shares of common stock in open‑market transactions. The sales, at prices of $204.39 and $203.75 per share, were made to satisfy tax withholding and remittance obligations arising from the vesting of Restricted Stock Units.
According to the filing, these transactions were executed under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, tied to stock unit agreements granted in January 2023 and January 2024. After these sales, Rabinowitz directly holds 223,024 shares of Natera common stock.
Natera, Inc. director and co‑founder Sheena Jonathan reported open‑market sales of 3,544 shares of Common Stock on April 27 and April 29, 2026, at prices around $196–$204 per share. After these trades, she directly holds 255,711 shares of Natera common stock.
Footnotes explain that certain sales were made to cover tax withholding and remittance obligations tied to the vesting of Restricted Stock Units and were effected pursuant to written instructions intended to satisfy Rule 10b5‑1(c) under the Exchange Act, including a trading plan adopted on December 11, 2024. Additional shares are held by the Caraluna 1 Trust and Caraluna 2 Trust, and Sheena Jonathan disclaims beneficial ownership of those trust securities.